Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAKIR infliximab pharmacokinetic variability study in rheumatoid arthritis
2007-002752-42Phase 4Active
- Sponsor
- CHRU Tours
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in rheumatoid arthritis (RA), sponsored by CHRU Tours. Primary endpoint: Pharmacokinetic variability and pharmacokinetic-pharmacodynamic relationship of infliximab. Started Jul 2007; status: active.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-002752-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002752-42.